ROCHE · WA21493
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A Phase II multicenter, randomized, parallel-group, partially blinded dose-finding study, with placebo and Avonex® as controls, to evaluate the efficacy, assessed by new brain lesions on MRI, and safety of two ocrelizumab treatment regimens in patients with relapsing-remitting multiple sclerosis. EudraCT: 2007-006338-32
Sponsor: ROCHE
Phase: II
Area: Neuroimmunology